Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PYGL | P06737 | 12/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.41 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.40 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | CYP51A1 | Q16850 | 3/20 | 0.40 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7018810 | 0.87 | KMT2A (0.44) | PYGLMEN1RAB9AKMT2AATM | |
| SCHEMBL7109854 | 0.76 | PYGL (0.51) | PYGLMEN1RAB9AKMT2AATM | |
| SCHEMBL7016055 | 0.76 | HDAC6 (0.54) | HRH1 | |
| SCHEMBL7019880 | 0.76 | F10 (0.51) | PYGL | |
| SCHEMBL7012587 | 0.73 | F10 (0.54) | — | |
| SCHEMBL7014368 | 0.71 | LOXL2 (0.57) | PYGLMEN1RAB9AKMT2ASIRT1 | |
| SCHEMBL25200874 | 0.71 | SIRT1 (0.52) | MEN1KMT2ASIRT1HRH4HRH3 | |
| SCHEMBL7014365 | 0.68 | SIRT1 (0.60) | PYGLMEN1RAB9AKMT2ASIRT1 | |
| SCHEMBL4324479 | 0.67 | HRH4 (0.62) | PYGLMEN1RAB9AKMT2AATM | |
| SCHEMBL30222912 | 0.67 | SIRT1 (0.58) | MEN1RAB9AKMT2ASIRT1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-10-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030187023-A1 | Sulfone derivatives, process for their production and use thereof | SULT1E1, RRS1, SHH | PYGL 4465/4885MEN1 1401/4885RAB9A 1515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.